TICKERNERD
Menu
TNXPTNXPHealthcare · Biotechnology

TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$11
+6.59% on the day

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. hold a median 12-month price target of $34 — +218.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$159.6M
Ticker Nerd rank
18 / 100
Median analyst target
$34
Analysts covering
4
Total return, dividends reinvested
1W
+2.9%
1M
−13.5%
YTD
−31.7%
1Y
−72.6%
From 52W high
−82.7%
From 52W low
+12.2%
$10
$62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
70
Accruals
54
Revisions
54
Quality
45
Growth
39
Volatility
31
Issuance
16
Value
6
Momentum
4

Size (70): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership.

Wall Street

TNXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26TNXPHigh $65Median $34Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $22Median $34High $65

The green dot is the last close — the median target sits +218.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 June 2026Raymond JamesInitiatesStrong Buy$26
4 May 2026TD CowenInitiatesBuy—
20 Mar 2025Noble Capital MarketsReiteratesOutperform—
22 July 2024Alliance Global PartnersMaintainsBuy—
28 Feb 2024Dawson JamesInitiatesBuy—
1 Aug 2023Alliance Global PartnersMaintainsBuy—
2 June 2023Alliance Global PartnersMaintainsBuy—
12 Jan 2023Alliance Global PartnersReiteratesBuy$6.50
18 Apr 2022Noble Capital MarketsInitiatesOutperform$0.60
31 Aug 2021Alliance Global PartnersMaintainsBuy—
11 Aug 2021Alliance Global PartnersMaintainsBuy—
25 Feb 2021Alliance Global PartnersMaintainsBuy—
18 Nov 2019B. Riley FBRDowngradeNeutral—
18 Nov 2019Cantor FitzgeraldDowngradeHold—
18 Nov 2019Janney CapitalInitiatesBuy—
18 Nov 2019OppenheimerMaintainsOutperform—
18 Nov 2019Roth CapitalUpgradeBuy—
18 Apr 2019Roth CapitalUpgradeBuy—
27 July 2018B. Riley FBRDowngradeNeutral—
27 July 2018Roth CapitalDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TNXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tonix Pharmaceuticals Holding Corp. (TNXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
9.1×

Cheaper than 15% of US stocks

Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
183.2%

Higher than 96% of US stocks

Earnings growth (YoY)
183.2%

Higher than 91% of US stocks

Gross margin
77.1%

Higher than 89% of US stocks

Operating margin
−603.9%

Higher than 7% of US stocks

Net margin
49.3%

Higher than 95% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−41.9%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TNXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNXPTonix Pharmaceuticals Holding Corp.$159.6M
18
MENSJyong Biotech Ltd.$159.6M
3
TNYATenaya Therapeutics, Inc.$160.3M
57
IVVDInvivyd, Inc.$157.6M
26
ARCTArcturus Therapeutics Holdings, Inc.$163.7M
44
ABOSAcumen Pharmaceuticals, Inc.$155.3M
54
ALECAlector, Inc.$164.8M
45
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TNXP news & analysis

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

GlobeNewsWire · 3 Aug 2026positive

Tonix Pharmaceuticals announced it received positive minutes from a Type C FDA meeting on its adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody intended to prevent Lyme disease in the U.S. The company said FDA alignment on key study-design elements supports its planned start of the Phase 2 study in the first quarter of 2027.

Why it matters — FDA alignment on the study design clears a regulatory path for Tonix's Lyme disease prevention candidate, TNX-4800, to advance toward its planned Phase 2 start in early 2027.

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

GlobeNewsWire · 27 July 2026neutral

Tonix Pharmaceuticals announced it will release second quarter 2026 financial results and operational highlights on August 10, 2026, followed by a conference call and webcast at 8:30 a.m. ET.

Why it matters — TNXP watchers will gain insight into the company's financial performance and recent operational progress for the second quarter.

FAQ

Frequently asked questions about TNXP stock

What is the TNXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. have a median 12-month price target of $34, with estimates ranging from $22 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNXP stock a buy right now?

Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 18 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNXP?

As at 1 Aug 2026, Tonix Pharmaceuticals Holding Corp. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).

Will TNXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +218.7% from the last close, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 18 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNXP stock forecast for 2030?

No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $65 over the next 12 months.

How has TNXP stock performed over the past year?

Tonix Pharmaceuticals Holding Corp. returned -72.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering.

What is the latest news on TNXP?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.". Tonix Pharmaceuticals announced it received positive minutes from a Type C FDA meeting on its adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody intended to prevent Lyme disease in the U.S. The company said FDA alignment on key study-design elements supports its planned start of the Phase 2 study in the first quarter of 2027.

Company

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its primary emphasis is on central nervous system (CNS) disorders, including fibromyalgia and major depressive disorder, addressed by product candidates like TNX-102 SL, a sublingual cyclobenzaprine HCl tablet branded as TONMYA, now available by prescription as the first new FDA-approved fibromyalgia treatment in over 15 years. The company also markets Zembrace SymTouch and Tosymra for acute migraine treatment in adults. In immunology, it advances biologics such as TNX-1500, a humanized monoclonal antibody targeting CD40-ligand for organ transplant rejection, autoimmunity, and cancer. Additional pipelines cover infectious diseases like mpox and Lyme disease prevention with TNX-801 and TNX-4800, respectively, rare diseases including Prader-Willi Syndrome via TNX-2900, and other areas. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals Holding Corp. operates in the biotechnology sector, targeting unmet medical needs across multiple therapeutic domains.

CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com